• Company
• Imported API from China·India reaches 50%
• by Kim, Jin-Gu Jan 13, 2025 05:53am

• Company
• Sanofi’s Hexaxim is included in NIP from this year
• by Whang, byung-woo Jan 10, 2025 05:52am

• Policy
• Chinese pharma targeting KOR, BeiGene gets greenlight
• by Lee, Hye-Kyung Jan 10, 2025 05:52am

• Company
• Hexaxim may be administered in general hospitals in Korea
• by Eo, Yun-Ho Jan 10, 2025 05:52am

• Company
• Lilly Korea releases Ebglyss for atopic dermatitis in Korea
• by Whang, byung-woo Jan 10, 2025 05:52am

• Company
• Leclaza’s new trial data shows improved OS
• by Son, Hyung Min Jan 9, 2025 05:57am

• Company
• Vabysmo approved for retinal vein occlusion macular edema
• by Whang, byung-woo Jan 9, 2025 05:56am

• GC Biophara to offset Lipidil supra loss with new drug?
• by Lee, Tak-Sun Jan 9, 2025 05:56am

• Company
• Krazati receives orphan drug designation in Korea
• by Eo, Yun-Ho Jan 9, 2025 05:56am

• Policy
• AML treatment Mylotarg stalled at the DREC review
• by Lee, Tak-Sun Jan 9, 2025 05:56am